(RARE) Ultragenyx Pharmaceutical Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RARE) Ultragenyx Pharmaceutical Inc. Complete Analysis Pack
Ultragenyx’s Business Model, Simplified
Unlock the strategic blueprint behind Ultragenyx Pharmaceutical Inc.’s business model. This concise Business Model Canvas shows how the company creates value through rare-disease therapies, partnerships, and a focused revenue strategy.
It’s a smart resource for investors, analysts, and business builders who want a clear view of the company’s strengths and growth drivers. Get the full version to explore all nine building blocks in detail.
Partnerships
10 collaboration and licensing partners
Ultragenyx Pharmaceutical Inc. relies on 10 named collaboration and licensing partners, including Kyowa Kirin, REGENXBIO, Bayer Healthcare, GeneTx, Mereo, Arcturus Therapeutics, Solid Biosciences, Daiichi Sankyo, Saint Louis University, and the University of Pennsylvania. This network helps fund and share risk across rare-disease discovery, development, and commercialization across multiple programs.
Kyowa Kirin and REGENXBIO programs
Kyowa Kirin and REGENXBIO are two key external partners for Ultragenyx Pharmaceutical Inc., helping it build biologic and gene-therapy programs without relying only on internal teams. In 2025, Ultragenyx still listed both relationships as important to its R&D engine, especially for shared technical know-how, platform access, and risk-spread development across rare-disease programs.
Academic research with Saint Louis University and UPenn
Ultragenyx works with Saint Louis University and the University of Pennsylvania to add disease expertise and translational insight, helping push rare-disease programs from concept into development. With rare diseases affecting more than 300 million people worldwide, these academic ties speed early science where clinical data are hardest to generate.
Bayer, GeneTx, and Mereo agreements
Ultragenyx Pharmaceutical Inc. uses Bayer Healthcare, GeneTx, and Mereo deals to expand access to platform tech and candidate assets while sharing the cost and risk of niche programs. These alliances support higher-value rare-disease shots such as GeneTx’s GTX-102 and Mereo’s setrusumab, which help spread R&D spend across partners.
- Bayer, GeneTx, Mereo broaden pipeline reach
- Shared risk lowers solo development burden
Arcturus, Solid Biosciences, and Daiichi Sankyo
Ultragenyx’s partnerships with Arcturus Therapeutics, Solid Biosciences, and Daiichi Sankyo give it 3 outside engines for mRNA, gene therapy, and global development. This mix helps spread R&D risk and supports rare-disease programs that need specialized science and cross-border trial execution.
- 3 key partners across advanced modalities
- Supports rare genetic disease pipeline
- Expands global development reach
Ultragenyx’s 10 Partners Power Rare-Disease R&D
Ultragenyx Pharmaceutical Inc. leans on 10 named partners to share R&D risk and speed rare-disease work: Kyowa Kirin, REGENXBIO, Bayer Healthcare, GeneTx, Mereo, Arcturus Therapeutics, Solid Biosciences, Daiichi Sankyo, Saint Louis University, and the University of Pennsylvania. In 2025, these ties still supported platform access, disease insight, and global trial execution.
| Partner count | Main value |
|---|---|
| 10 | Shared risk, tech access, academic input |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Ultragenyx Pharmaceutical Inc. covering its strategy, customers, and core value drivers.
Customizable Excel Spreadsheet
Clarifies Ultragenyx Pharmaceutical Inc.’s business model pain points in one editable, board-ready snapshot.
Reference Sources
Helps validate Ultragenyx assumptions quickly with traceable sources, boosting confidence for due diligence and decision-making.
Activities
4 marketed rare-disease therapies commercialization
Ultragenyx commercializes 4 marketed rare-disease therapies, including Crysvita, Mepsevii, Dojolvi, and Evkeeza, across relevant markets. This means launch execution, supply planning, and physician education, plus access support for specialty drugs with complex reimbursement and distribution.
6 named pipeline programs
Ultragenyx Pharmaceutical Inc. is advancing 6 named pipeline programs: DTX401, DTX301, UX143, GTX-102, UX701, and UX053. They span gene therapy, antibody, antisense, and other modalities, so execution across this 6-program engine is central to future growth.
Clinical development in rare genetic disease
Ultragenyx Pharmaceutical Inc. runs clinical development in ultra-rare genetic diseases, where patient pools are tiny and endpoints must track real functional change, not just broad lab shifts. The company’s rare-disease model is built around high unmet need programs and small, tightly defined studies, so trial design, site selection, and enrollment speed are as important as the drug itself.
Regulatory and market access execution
Ultragenyx Pharmaceutical Inc. runs regulatory and market access work across 3 main regions: North America, Europe, and other international markets. That means pushing approvals, labeling, and reimbursement at the same time, because in rare disease, access can matter as much as approval.
- Works through FDA and EMA pathways
- Supports label and payer decisions
- Access speed drives rare-disease sales
Global supply and lifecycle management
Ultragenyx Pharmaceutical Inc. runs global biologic and gene-therapy supply chains to keep rare-disease medicines quality-controlled, on time, and available to patients. With 4 approved therapies and a late-stage pipeline of 10+ programs, lifecycle work helps extend existing products into new indications and support follow-on launches without breaking supply continuity.
- Protect quality and continuity
- Keep patient supply available
- Scale biologic and gene-therapy logistics
- Support new indications and launches
Ultragenyx: 4 therapies, 6 pipeline programs, 3 regions
Ultragenyx Pharmaceutical Inc. key activities center on 4 marketed rare-disease therapies, 6 named pipeline programs, and execution across 3 regions. The work is launch support, clinical development, regulatory filings, and access planning for small patient groups where speed and reimbursement matter most.
| Area | Count |
|---|---|
| Marketed therapies | 4 |
| Named pipeline programs | 6 |
| Main regions | 3 |
Full Version Awaits
Business Model Canvas
The Ultragenyx Pharmaceutical Inc. Business Model Canvas previewed here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see is the real file, formatted and structured the same way. Once purchased, you’ll get the complete version instantly, ready to edit, share, or present.
Resources
4 marketed products
Ultragenyx Pharmaceutical Inc.’s 4 marketed products—Crysvita, Mepsevii, Dojolvi, and Evkeeza—give it current revenue, rare-disease brand visibility, and a base to fund its pipeline. Crysvita remains the anchor asset, while the other 3 approvals show the platform can move programs from R&D into commercial use.
6 pipeline assets
Ultragenyx Pharmaceutical Inc. relies on 6 core pipeline assets: DTX401, DTX301, UX143, GTX-102, UX701, and UX053. Each targets a serious rare genetic disorder with few or no approved options, so these programs are the main source of long-term growth and future revenue potential.
10 strategic partnership agreements
Ultragenyx Pharmaceutical Inc. lists 10 strategic partnership agreements as a key resource, giving it access to partner technology, scientific know-how, and development support. This network lets the company expand its rare-disease pipeline without owning every platform in-house.
Rare-disease know-how since 2010
Founded in 2010, Ultragenyx Pharmaceutical Inc. has built 15 years of rare-disease know-how that is hard to copy. That intangible asset helps it find patients, shape trials, and launch therapies in small, complex markets; in 2025, that expertise backed a portfolio of 4 approved products and ongoing rare-disease programs.
- Founded in 2010
- 15 years of rare-disease focus
- Supports patient ID, trials, launch
- 4 approved products in 2025
Novato, California headquarters
Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California, and the site anchors executive leadership, R&D oversight, and global coordination for its rare-disease portfolio. The company reported $1.8 billion in 2024 revenue, and the Novato hub supports operations across North America, Europe, and other markets.
- Novato HQ: leadership and oversight
- Supports global commercial coordination
- Backs North America and Europe
Ultragenyx’s 2025 Edge: 4 Products, 6 Pipeline Assets, 10 Partnerships
Ultragenyx Pharmaceutical Inc.’s key resources are 4 approved rare-disease products, 6 major pipeline assets, and 10 strategic partnerships, plus 15 years of rare-disease know-how. In 2025, that mix supported commercial revenue, trial execution, and long-term growth optionality.
| Resource | 2025 snapshot |
|---|---|
| Approved products | 4 |
| Pipeline assets | 6 |
| Partnerships | 10 |
Value Propositions
Targeted treatments for rare and ultra-rare genetic diseases
Ultragenyx focuses on rare and ultra-rare inherited diseases with very small patient pools, where treatment options are limited and unmet need is high. Its specialty model spans several FDA-approved therapies, including Crysvita and Dojolvi, and this narrow focus helps it stand apart from broader biopharma peers that spread R&D across larger markets.
4 commercial therapies across multiple diseases
Ultragenyx Pharmaceutical Inc. already markets 4 therapies in rare disease, giving it an established commercial base and near-term patient impact. In 2025, Company Name reported annual revenue of about $640 million, led by approved drugs that show it can turn science into medicines patients use.
Multiple modalities: biologic, enzyme, gene, antisense
Ultragenyx uses several modalities instead of one platform: Crysvita is an antibody biologic, Mepsevii is enzyme replacement, and pipeline assets include gene and oligo-based programs. That mix helps Ultragenyx match the right therapy to the right rare disease, which is key in a pipeline spanning dozens of rare and ultra-rare indications.
Pipeline depth in 6 high-need programs
Ultragenyx Pharmaceutical Inc. has 6 high-need programs spanning glycogen storage disease, ornithine transcarbamylase deficiency, osteogenesis imperfecta, Angelman syndrome, Wilson disease, and GSD III, all aimed at rare diseases with few or no effective options. That breadth gives the company multiple shots at future value creation if even one late-stage asset converts.
- 6 programs in rare, high-need markets
- Targets diseases with few treatments
- Supports long-term pipeline value
International rare-disease reach
Ultragenyx Pharmaceutical Inc. sells rare-disease therapies across North America, Europe, and other international markets, so it can reach more patients with very small disease pools. That footprint also supports global evidence generation and smoother launch execution, which helps each new therapy build demand beyond one region.
- Broader patient access
- More launch flexibility
- Stronger real-world evidence
Ultragenyx’s rare-disease niche is already driving real revenue
Ultragenyx Pharmaceutical Inc. targets rare and ultra-rare diseases where approved options are scarce, and its 4 marketed therapies give it real patient reach. In 2025, Company Name reported about $640 million in revenue, showing that this niche model is already monetizing.
| Key value prop | 2025 data |
|---|---|
| Marketed therapies | 4 |
| Revenue | $640 million |
Customer Relationships
Specialist physician engagement
Ultragenyx Pharmaceutical Inc. leans on rare-disease specialists to find and treat patients in a market built on 3 marketed therapies and a deep pipeline. These physicians handle complex genetic diagnoses and write specialty prescriptions, so regular scientific exchange is key to adoption and persistence.
High-touch patient support
Ultragenyx Pharmaceutical Inc.’s high-touch model fits rare disease care: about 300 million people worldwide live with a rare disease, and many need help starting therapy, staying on it, and coordinating follow-up. This is more hands-on than mass-market pharma, so Ultragenyx must keep patients, caregivers, and specialists aligned over long treatment cycles.
Access and reimbursement support
Access and reimbursement support is central for Ultragenyx Pharmaceutical Inc. because rare-disease therapies are high-cost specialty drugs, often priced at six figures per patient each year, so payer approval can make or break use. With rare diseases affecting about 300 million people worldwide, Ultragenyx must help patients and providers navigate coverage, prior auth, and appeals to turn launches into real sales.
Long-term therapy management
Ultragenyx Pharmaceutical Inc. builds long-term therapy management around chronic treatments such as Crysvita, Dojolvi, and Evkeeza, so patients need repeat support on safety, dosing, and continuity. In 2025, that model helped drive steadier follow-up and higher retention across ongoing therapy lines.
- Chronic use means repeat patient touchpoints.
- Safety and dosing support improve continuity.
- Ongoing care supports retention and outcomes.
Rare-disease community collaboration
Ultragenyx Pharmaceutical Inc. works in very small, expert rare-disease communities, so patient groups, caregivers, and advocacy networks strongly shape awareness and diagnosis. This close collaboration helps the company spot unmet needs early and refine support around diseases with only a few thousand known patients.
- Patient advocates speed diagnosis.
- Caregivers surface unmet needs.
- Community trust supports awareness.
Ultragenyx Wins on Rare-Disease Trust and Coverage Support
Ultragenyx Pharmaceutical Inc. uses a high-touch model with rare-disease specialists, patients, caregivers, and payer teams, because adoption depends on diagnosis, coverage, and long-term follow-up. About 300 million people worldwide live with a rare disease, so these relationships are built for chronic, specialty care.
In 2025, support around dosing, safety, prior auth, and appeals helped keep patients on Crysvita, Dojolvi, and Evkeeza, where treatment can cost six figures per year. That makes trust and reimbursement support central to retention.
| Metric | Data |
|---|---|
| Rare disease population | 300 million worldwide |
| Therapy model | High-touch, chronic care |
| Key support | Coverage, dosing, safety |
Channels
Specialty physicians and treatment centers
Ultragenyx reaches patients through rare-disease specialists and treatment centers, the key channel for diagnosis, prescribing, and ongoing monitoring. In 2025, this matters even more because specialty medicines like VOXZOGO and Crysvita depend on expert clinics, not broad primary-care prescribing, to drive access and adherence.
Hospitals and infusion sites
Ultragenyx Pharmaceutical Inc. uses hospitals and infusion sites for enzyme and biologic therapies such as Mepsevii and Crysvita, where trained staff can administer treatment, monitor reactions, and keep patients safe. These sites matter because infused rare-disease care often needs dose prep, observation, and rapid response to infusion-related events.
Specialty pharmacy distribution
Ultragenyx Pharmaceutical Inc. uses specialty pharmacy channels for its rare-disease medicines because they need controlled access, cold-chain handling, and patient-specific dispensing. This setup also supports refill tracking and adherence workflows, which is critical for therapies used by small patient groups; in the U.S., specialty drugs now account for about 50% of drug spend.
Direct commercial and medical teams
Ultragenyx relies on direct commercial and medical teams to educate specialists, support launches, and explain clinical data in rare diseases, where patient pools are often very small. This high-touch model matters because field and medical affairs staff can move faster than broad channel marketing when adoption depends on provider trust and tight launch execution.
- Direct, specialist-led education
- Medical affairs explains trial data
- Best for small rare-disease markets
International partners and local affiliates
Ultragenyx Pharmaceutical Inc. uses regional partners and local affiliates outside the United States to sell and support products in country-specific markets. This helps handle reimbursement, pricing, and regulatory reviews faster, while keeping global reach broad without building full sales teams in every market.
- Local partners manage market access
- Regional deals extend ex-U.S. reach
- Lower fixed cost than direct launch
Ultragenyx’s High-Touch Rare-Disease Sales Model Explained
Ultragenyx Pharmaceutical Inc. sells rare-disease drugs through specialist clinics, hospitals, and specialty pharmacies, with direct field teams and medical affairs supporting diagnosis, access, and adherence. This high-touch model fits small patient pools and complex therapies like VOXZOGO and Crysvita, while ex-U.S. partners extend reach without full local sales builds.
| Channel | Use |
|---|---|
| Specialists | Diagnose, prescribe |
| Hospitals | Infusion, monitoring |
| Specialty pharmacy | Cold-chain, refills |
| Partners | Ex-U.S. access |
Customer Segments
Pediatric and adult rare-disease patients
Ultragenyx serves pediatric and adult patients with inherited metabolic and genetic disorders; its medicines target the core rare-disease population, which affects about 300 million people worldwide and often begins in childhood. These patients are the direct end users for therapies such as Crysvita, Dojolvi, and Mepsevii, which are used across both age groups.
Families and caregivers
Families and caregivers are the real operators in Ultragenyx Pharmaceutical Inc.’s pediatric rare disease market: they manage appointments, therapy routines, and support services, and they heavily shape treatment choice. About 70% of rare diseases start in childhood, so caregiver needs directly drive patient support design and adherence.
Specialists in metabolic and genetic medicine
Specialists in metabolic and genetic medicine are a core customer segment for Ultragenyx Pharmaceutical Inc.; these physicians diagnose rare disorders such as XLH, MPS VII, and OTC deficiency, and their trust often drives specialty therapy use. That matters in a market where XLH alone affects about 1 in 20,000 people, so fast diagnosis and physician confidence can directly shape treatment uptake.
Hospitals and rare-disease centers
Hospitals and rare-disease centers are key customers for Ultragenyx Pharmaceutical Inc. because rare diseases affect about 300 million people worldwide, and these sites handle complex diagnosis, infusion delivery, and long-term monitoring. They also coordinate multidisciplinary care, which matters for specialty therapies that need trained staff and strict administration.
- 300 million people live with rare disease
- Best fit for infusion-based therapies
- Supports multidisciplinary care teams
Payers and health systems
Ultragenyx relies on payers and health systems to win access, since prior authorization, step edits, and formulary placement can slow rare-disease uptake. These buyers judge both clinical benefit and budget impact, so each reimbursement win or loss can move prescription volume fast.
- Access rules shape uptake
- Clinical value drives coverage
- Budget impact drives restrictions
Ultragenyx Targets Rare Disease Care With High-Stakes Access Wins
Ultragenyx Pharmaceutical Inc. serves patients with rare inherited metabolic and genetic diseases, especially children and adults with XLH, MPS VII, and OTC deficiency; rare diseases affect about 300 million people worldwide, and about 70% start in childhood.
Its buyers also include caregivers, specialists, hospitals, and payers, because diagnosis, infusion care, and reimbursement rules drive access and uptake. XLH affects about 1 in 20,000 people, so specialist trust and coverage wins matter fast.
| Segment | Need |
|---|---|
| Patients | Rare-disease therapy |
| Caregivers | Adherence support |
| Payers | Coverage control |
Cost Structure
R&D and discovery spending
Ultragenyx Pharmaceutical Inc. keeps R&D and discovery spending as a core cost driver, funding lab research, preclinical studies, and platform development for its rare-disease pipeline. This spend stays high because new programs need long testing cycles and heavy scientific input before they can reach clinical trials.
Clinical trial and regulatory costs
Ultragenyx Pharmaceutical Inc. clinical trial and regulatory spend is heavy because rare-disease studies often enroll only tens to low hundreds of patients, yet still need site setup, monitoring, data capture, and FDA/EMA filings. In 2025, that spend stayed tied to late-stage programs like GTX-102 and UX111, where each submission can drive approval and label expansion.
Biologic and gene-therapy manufacturing
Biologic and gene-therapy manufacturing is one of Ultragenyx Pharmaceutical Inc.’s biggest cost lines because antibodies, enzymes, and viral-vector therapies need tight process control, sterile facilities, and batch-release testing. This is why quality systems and supply reliability matter so much: one failed batch can wipe out months of output and push per-unit costs sharply higher.
Commercial, medical, and access operations
Ultragenyx Pharmaceutical Inc. spends on sales teams, medical affairs, and reimbursement support to reach rare-disease patients, where each U.S. disease often affects fewer than 200,000 people. That spend helps educate prescribers, speed payer access, and keep therapy persistence high. Rare-disease launches are people-heavy, not volume-heavy.
- Sales, medical affairs, reimbursement support
- Built for low-patient specialty markets
- Supports education and persistence
Collaboration, licensing, and SG&A
Ultragenyx's partner-heavy model keeps collaboration and license payments in the cost base, while SG&A funds corporate, finance, legal, and commercial support. In 2025, these overhead costs remained a major cash use as the Company scaled a multi-program rare-disease portfolio.
- External partnerships drive recurring fees
- IP licenses add fixed cost pressure
- SG&A supports the full organization
Ultragenyx’s 2025 Costs Stay High on R&D, Trials, and Gene-Therapy Output
Ultragenyx Pharmaceutical Inc. cost structure is dominated by R&D, clinical trials, gene-therapy manufacturing, and specialty-commercial support, with SG&A and partner fees adding steady overhead. In 2025, these costs stayed high because the Company kept funding late-stage rare-disease programs and global regulatory work.
| Cost line | 2025 focus |
|---|---|
| R&D | Pipeline and platform spend |
| Clinical/regulatory | Late-stage trials, filings |
| Manufacturing | Biologic and gene-therapy output |
| SG&A / partners | Commercial support and licenses |
Revenue Streams
Crysvita product sales
Crysvita is one of Ultragenyx Pharmaceutical Inc.'s key commercial assets, with sales from approved markets for X-linked hypophosphatemia and tumor-induced osteomalacia. In 2025, it stayed a core revenue driver, supported by 2 major approved indications and broad physician use in rare bone disease.
Its product sales matter because they help fund the company’s rare-disease portfolio and R&D pipeline.
Mepsevii product sales
Mepsevii product sales add a small, recurring enzyme replacement revenue stream for MPS VII, an ultra-rare disease with only a tiny eligible patient pool. Because uptake depends on specialty pharmacy access and diagnosis rates, sales are lumpy, but the product still broadens Ultragenyx Pharmaceutical Inc.'s rare-disease mix beyond its larger franchises.
Dojolvi product sales
Dojolvi product sales come from triheptanoin treatment for long-chain fatty acid oxidation disorders, creating recurring prescription revenue rather than one-time sales. It also widens Ultragenyx Pharmaceutical Inc. beyond a single disease focus; as a branded rare-disease therapy, Dojolvi has been part of the company’s commercial portfolio since its U.S. launch in 2019.
Evkeeza and other marketed product sales
Ultragenyx Pharmaceutical Inc. also earns revenue from Evkeeza sales in eligible territories, adding a second commercial leg alongside its own marketed drugs. This stream improves top-line mix, but it still depends on launch execution, payer coverage, and patient access, so uptake can swing quarter to quarter.
- Evkeeza broadens commercial revenue
- More products reduce single-asset risk
- Access and execution drive sales
Milestones, royalties, and collaboration revenue
Ultragenyx Pharmaceutical Inc.'s partnered programs can add non-product income through milestone and royalty payments, so revenue can rise as co-development assets advance or licensed products sell. This collaboration-led stream helps diversify earnings beyond its own medicines, and in 2025 the company still reported collaboration revenue alongside product sales.
- Milestones: paid on program progress
- Royalties: tied to partner sales
- Collaboration revenue: non-product income
Ultragenyx 2025 Revenue: Crysvita Drives the Mix
In 2025, Ultragenyx Pharmaceutical Inc.'s revenue came mainly from Crysvita, with added sales from Mepsevii, Dojolvi, and Evkeeza, plus collaboration revenue from partnered programs. The mix is still rare-disease heavy, so product access, diagnosis, and payer coverage remain the main sales drivers.
| Revenue stream | 2025 role |
|---|---|
| Crysvita | Core product sales |
| Mepsevii | Small recurring sales |
| Dojolvi | Recurring prescription sales |
| Evkeeza | Partnered product sales |
| Collaboration revenue | Milestones and royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.